Liposomal form of 2-alkylthioimidazolone-based copper complexes for combined cancer therapy.
Tamara M IakimovaAnna A BubleyOlga P BoychenkoDmitry A GukAlexander N VaneevAndrey N PrusovAlexander S ErofeevPeter V GorelkinOlga O KrasnovskayaNatalia L KlyachkoKseniya Yu VlasovaPublished in: Nanomedicine (London, England) (2023)
Aim: To develop an optimized approach for encapsulating a 2-alkylthioimidazolone-based copper coordination compound within liposomes, which could offer treatment of cancer and bacterial infections by reactive oxygen species generation toxicity mechanisms. Materials & methods: For drug-loaded liposome preparation, lipids and drug mixture in organic solvents was injected into copper salt solution, forming a coordination compound simultaneously embedded in the lipid bilayer. In vitro tests were performed on MCF7 and MDA-MB-231 breast cancer cells. Results: Liposomes had a loading capacity of up to 1.75% (molar drug-to-lipid ratio). In vitro tests showed increased viability and accumulation of the liposomal formulation compared with free drug as well as lack of cytotoxicity in hepatocytes. Conclusion: This optimized technique for encapsulating large copper complexes in liposomes could be used to improve their delivery and better treat cancer and bacterial infections.